Isolated limb infusion: A review

Journal of Surgical Oncology

Volumn 100, Issue 2, 2009, Pages 169-177

  Kroon, Hidde M ^a   Thompson, John F ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Actinomycin D; Hypoxia; Isolated limb infusion; Melphalan; Regional chemotherapy; Regional metastatic melanoma

Indexed keywords

MELPHALAN;

ADVANCED CANCER; CANCER INVASION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; LIMB PERFUSION; MELANOMA; MINIMALLY INVASIVE PROCEDURE; NONHUMAN; PATIENT SATISFACTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SARCOMA; TREATMENT RESPONSE;

ANIMALS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; HUMANS; MELANOMA; MELPHALAN; PROGNOSIS; SARCOMA; VASCULAR DISEASES;

EID: 67749124393     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21280     Document Type: Review

References (75)

1. Thompson JF, Lai DT, Ingvar C, et al.: Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res 1994;4S:45-50. (Pubitemid 24144674)
2. Vrouenraets BC, Nieweg OE, Kroon BBR: Thirty-five years of isolated limb perfusion: Indications and results. Br J Surg 1996; 83:1319-1328.
3. Thompson JF, Hunt JA, Shannon KF, et al.: Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997;132:903-907. (Pubitemid 27344144)
4. Noorda EM, Vrouenraets BC, Nieweg OE, et al.: Isolated limb perfusion: What is the evidence for its use? Ann Surg Oncol 2004; 11:837-845.
5. Kroon BB, Klaase JM, van Geel BN, et al.: Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb. Eur J Cancer 1993;29A:325-328.
6. Liénard D, Eggermont AM, Kroon BBR, et al.: Isolated limb perfusion in primary and recurrent melanoma: Indications and results. Semin Surg Oncol 1998;14:202-209. (Pubitemid 28146511)
7. Grünhagen DJ, van Etten B, Brunstein F, et al.: Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol 2005;12:609-615. (Pubitemid 41126090)
8. Karakousis CP, Kanter PM, Lopez R, et al.: Modes of regional chemotherapy. J Surg Res 1979;26:134-141.
9. Karakousis CP, Kanter PM, Park HC, et al.: Tourniquet infusion versus hyperthermic perfusion. Cancer 1982;49:850-858.
10. Bland KI, Kimura AK, Brenner DE, et al.: A phase II study of the efficacy of diamminedichloroplatinum for the control of locally recurrent and intransit malignant melanoma of the extremities using tourniquet outflow-occlusion techniques. Ann Surg 1989; 209:73-80.
11. Thompson JF,Waugh RC, Saw RPM, et al.: Isolated limb infusion with melphalan for recurrent limb melanoma: A simple alternative to isolated limb perfusion. Reg Cancer Treat 1994;7: 188-192.
12. Thompson JF, Kam PC, Waugh RC, et al.: Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion. Semin Surg Oncol 1998;14:238-247.
13. Lindnér P, Doubrovsky A, Kam PCA, et al.: Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002;9:127-136. (Pubitemid 34259697)
14. Kroon HM, Moncrieff M, Kam PC, et al.: Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 2008;15:3003-3013.
15. Sanki A, Kam PCA, Thompson JF: Long-term results of hyperthermic, isolated limb perfusion for melanoma. Ann Surg 2007;4:591-596.
16. Brady MS, Brown K, Patel A, et al.: A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 2006;13:1123-1129. (Pubitemid 44337972)
17. Beasley GM, Petersen RP, Yoo J, et al.: Isolated limb infusion for in-transit malignant melanoma of the extremity: A well tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008;15:2195-2205.
18. Mian R, Henderson MA, Speakman D, et al.: Isolated limb infusion for melanoma: A simple alternative to isolated limb perfusion. Can J Surg 2001;44:189-192. (Pubitemid 32538770)
19. Marsden J, Samarasinghe V, Duddy M, et al.: Regional chemotherapy for inoperable limb cancer using isolated limb infusion. Br J Dermatol 2008;159:10.
20. Minor DR, Allen RE, Alberts DE, et al.: A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 1985;55:2638-2644.
21. Kroon HM, Moncrieff M, Kam PCA, et al.: Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Ann Surg Oncol. [Epub ahead of print].
22. Vrouenraets BC, Klaase JM, Nieweg OE, et al.: Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol 1998; 14:224-231. (Pubitemid 28146514)
23. Hegazy MA, Kotb SZ, Sakr H, et al.: Preoperative isolated limb infusion of Doxorubicin and external irradiation for limb-threatening soft tissue sarcomas. Ann Surg Oncol 2007;14:568-576. (Pubitemid 46175302)
24. Moncrieff M, Kroon HM, Kam PC, et al.: Results of isolated limb infusion in advanced soft tissue sarcoma of the extremity. Ann Surg Oncol 2008;15:2749-2756.
25. Damian DL, Barnetson RS, Rose BR, et al.: Treatment of refractory hand warts by isolated limb infusion with melphalan and actinomycin-D. Australas J Dermatol 2001;42:106-109. (Pubitemid 32436763)
26. Damian DL, Barnetson RS, Thompson JF: Treatment of refractory chromomycosis by isolated limb infusion with melphalan and actinomycin D. J Cutan Med Surg 2006;10:48-51.
27. Elhassadi E, Egan E, O'sullivan G, et al.: Isolated limb infusion with cytotoxic agent for treatment of localized refractory cutaneous T-cell lymphoma. Clin Lab Haematol 2006;28:279-281.
28. Schraffordt Koops H, Lejeune FJ, Kroon BBR, et al.: Isolated limb perfusion for melanoma: Technical aspects. In: Thompson JF, Morton DL, Kroon BBR, editors. Textbook of melanoma. London: Martin Dunitz; 2004. pp. 404-409.
29. Thompson JF, Kam PCA, de Wilt JHW, et al.: Isolated limb infusion for melanoma. In: Thompson JF, Morton DL, Kroon BBR, editors. Textbook of melanoma. London: Martin Dunitz; 2004. pp. 429-437.
30. Thompson JF, Kam PC, Waugh RC, et al.: Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion. Semin Surg Oncol 1998;14:238-247.
31. Kroon BBR, Noorda EM, Vrouenraets BC, et al.: Isolated limb perfusion for melanoma. J Surg Oncol 2002;79:252-255.
32. Thompson JF, Siebert GA, Anissimov YG, et al.: Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Br J Cancer 2001; 85:157-165. (Pubitemid 32700296)
33. Wu ZY, Smithers BM, Roberts MS: Melphalan dosing regimens for management of recurrent melanoma by isolated limb perfusion: Application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb. Melanoma Res 1997;7:252-264.
34. Scott RN, Kerr DJ, Blackie R, et al.: The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma. Br J Cancer 1992;66:159-166.
35. Thompson JF, Ramzan I, Kam PCA, et al.: Pharmacokinetics of melphalan during isolated limb infusion for melanoma. Reg Cancer Treat 1996;9:13-16. (Pubitemid 26360195)
36. Roberts MS, Wu ZY, Siebert GA, et al.: Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res 2001;11: 423-431.
37. DeWilt JHW, Manusama ER, van Tiel ST, et al.: Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 1999;80:161-166. (Pubitemid 29210102)
38. Benckhuijsen C, Kroon BBR, van Geel AN, et al.: Regional perfusion treatment with melphalan for melanoma in a limb: An evaluation of drug kinetics. Eur J Surg Oncol 1988;14:157-163. (Pubitemid 18110114)
39. Norda A, Loos U, Sastry M, et al.: Pharmacokinetics of melphalan in isolated limb perfusion. Cancer Chemother Pharmacol 1999; 43:35-42. (Pubitemid 29048346)
40. Wu ZY, Smithers BM, Roberts MS: Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb. J Pharmacol Exp Ther 1997;282:1131-1138. (Pubitemid 27408287)
41. Cavaliere R, Ciocatto EC, Giovanella BC, et al.: Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 1967;20:1351-1381.
42. Kroon BBR: Regional isolation perfusion in melanoma of the limbs: Accomplishments, unsolved problems, future. Eur J Surg Oncol 1988;14:101-110.
43. Wu ZY, Smithers BM, Parsons PG, et al.: The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft. Br J Cancer 1997;75:1160-1166.
44. Wieberdink J, Benckhuijsen C, Braat RP, et al.: Dosimetry in isolated perfusion of the limbs by assessment of perfused tissue and grading of toxic reactions. Eur J Cancer Clin Oncol 1982; 18:905-910.
45. Lai DTM, Ingvar C, Thompson JF: The value of monitoring serum creatine phosphokinase values following hyperthermic isolated limb perfusion for melanoma. Reg Cancer Treat 1993;6: 36-39. (Pubitemid 23287902)
46. Möller MG, Lewis JM, Dessureault S, et al.: Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperth 2008;24:275-289.
47. Vrouenraets BC, Hart GA, Eggermont AM, et al.: Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg 1999;188: 522-530. (Pubitemid 29214366)
48. Klaase JM, Kroon BB, Beijnen JH, et al.: Melphalan tissue concentration in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer 1994;70:151-153. (Pubitemid 24203644)
49. Klaase JM, Kroon BB, van Slooten GW, et al.: Relation between calculated melphalan peak concentrations and toxicity in regional isolated perfusion for melanoma. Reg Cancer Treat 1992;4:309-312.
50. Kroon HM, Lin DY, Kam PCA, et al.: Efficacy of repeat isolated limb infusion with melphalan and actinomycin-D for recurrent melanoma. Cancer. [Epub ahead of print].
51. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatments (WHO Offset Publication No. 48). Geneva: World Health Organization; 1979.
52. Cornett WR, McCall LM, Petersen RP, et al.: Prospective randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone versus melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006;24:4196-4201.
53. Klaase JM, Kroon BBR, van Geel AN, et al.: Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg 1994;178:564-572. (Pubitemid 24172563)
54. Siemann DW, Chapman M, Beikirch A: Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int J Radiat Oncol Biol Phys 1991;20:287-289.
55. Chaplin DJ, Acker B, Olive PL: Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs. Int J Radiat Oncol Biol Phys 1989;16:1131-1135. (Pubitemid 19137197)
56. Skarsgard LD, Skwarchuk MW, Vinczan A, et al.: The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res 1995;15:219-223.
57. DeVita VT: Principles of cancer management: Chemotherapy. In: De Vita ST, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. 5th edition. Philadelphia: Lippincott; 1997. pp. 333-348.
58. Lindnér P, Thompson JF, De Wilt JH, et al.: Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. Eur J Surg Oncol 2004;30:433-439. (Pubitemid 38528929)
59. Noorda EM, Vrouenraets BC, Nieweg OE, et al.: Repeat isolated limb perfusion with TNF-α and melphalan for recurrent limb melanoma after failure of previous perfusion. Eur J Surg Oncol 2006;32:318-324.
60. Feldman AL, Alexander HR, Jr., Bartlett DL, et al.: Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. Ann Surg Oncol 1999;6: 562-567.
61. Bonenkamp JJ, Thompson JF, de Wilt JH, et al.: Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur J Surg Oncol 2004;30:1107-1112.
62. Yoshimoto Y, Augustine CK, Yoo JS, et al.: Defining regional infusion treatment strategies for extremity melanoma: Comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. Mol Cancer Ther 2007;6:1492-1500. (Pubitemid 46954016)
63. Ueno T, Ko SH, Grubbs E: Modulation of chemotherapy resistance in regional therapy: A novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. Mol Cancer Ther 2006;5:732-738.
64. Grünhagen DJ, de Wilt JH, van Geel AN, et al.: Isolated limb perfusion for melanoma patients - A review of its indications and the role of tumour necrosis factor-alpha. Eur J Surg Oncol 2006; 32:371-380.
65. Liénard D, Eggermont AM, Schraffordt Koops H, et al.: Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: A multicenter randomized phase II study. Melanoma Res 1999;9:491-502. (Pubitemid 29494115)
66. Gutman M, Sofer D, Lev-Chelouche D, et al.: Synergism of tumor necrosis factor-alpha and melphalan in systemic and regional administration: Animal study. Invasion Metastasis 1997;17:169-175. (Pubitemid 28495382)
67. Nooijen PT, Manusama ER, Eggermont AM, et al.: Synergistic effects of TNF-alpha and melphalan in an isolated perfusion model of rat sarcomas: A histological, immunohistochemical and electron microscopic study. Br J Cancer 1996;74:1908-1915.
68. Hoekstra HJ, van Ginkel RJ: Hyperthermic isolated limb perfusion in the management of extremity sarcoma. Curr Opin Oncol 2003;15:300-303. (Pubitemid 36994034)
69. Noorda EM, Vrouenraets BC, Nieweg OE, et al.: Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 2002;9:968-974. (Pubitemid 35424630)
70. van Etten B, van Geel AN, de Wilt JH, et al.: Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol 2003;10: 32-37.
71. McMasters KM: Isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 2002;9:939-940. (Pubitemid 35424625)
72. Thompson JF, De Wilt JHW: Isolated limb perfusion in the management of patients with recurrent limb melanoma: An important but limited role. Ann Surg Oncol 2001;8:564-565.
73. Kroon HM, Lin DY, Kam PC, et al.: Safety and efficacy of isolated limb infusion in elderly patients with advanced locoregional melanoma. Eur J Surg Oncol 2008;34:1041.
74. Sonneveld EJ, Vrouenraets BC, van Geel BN, et al.: Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Eur J Surg Oncol 1996;22:521-527. (Pubitemid 26386017)
75. Thompson JF, Kam PC: Isolated limb infusion for melanoma: A simple but effective alternative to isolated limb perfusion. J Surg Oncol 2004;1:1-3. (Pubitemid 39313812)